AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33248595 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strains
Number of subjects: 20
Study 36169441 — intervention group
Group type: EXPERIMENTAL
Intervention: Beifushu eye drops (recombinant bovine basic fibroblast growth factor) 6 times daily for 1 week
Number of subjects: 118
Study 36169441 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate eye drops (artificial tears) 6 times daily for 1 week
Number of subjects: 118
Study 34647827 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cmH2O PEP during methacholine delivery
Number of subjects: 18
Study 34647827 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cmH2O PEP during the 3.5 min following methacholine delivery
Number of subjects: 18
Study 34647827 — intervention group
Group type: COMPARATOR
Intervention: No PEP
Number of subjects: 18
Study 32816096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (aerobic exercise 5-6 times/week, resistance exercise 2-3 times/week, dietary intervention aiming for BMI of 25 kg/m2)
Number of subjects: 98
Study 32816096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 98
Study 32816096 — intervention group
Group type: COMPARATOR
Intervention: Standard care (individual guidance on disease management, lifestyle advice, blinded regulation of medication)
Number of subjects: 98
Study 35389424 — intervention group
Group type: EXPERIMENTAL
Intervention: HD201
Number of subjects: 0
Study 35389424 — intervention group
Group type: COMPARATOR
Intervention: Referent Trastuzumab
Number of subjects: 0
Study 32118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory reserve measurement (CRM)
Number of subjects: 100
Study 35286051 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Exercise (MIE)
Number of subjects: 30
Study 35286051 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MCE)
Number of subjects: 30
Study 35286051 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 35286051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise betatrophin levels
Number of subjects: 30
Study 35286051 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with obesity markers
Number of subjects: 30
Study 32848901 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-based multi-task cognitive training
Number of subjects: 90
Study 32848901 — intervention group
Group type: COMPARATOR
Intervention: Health education (Control)
Number of subjects: 90
Study 35490877 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional memory reactivation electroconvulsive therapy (EMR-ECT)
Number of subjects: 72
Study 35490877 — intervention group
Group type: COMPARATOR
Intervention: Control memory reactivation electroconvulsive therapy (CMR-ECT)
Number of subjects: 72
Study 35490877 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EMR-ECT and CMR-ECT
Number of subjects: 72
Study 34243746 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated support system (linking hospital outpatient physiotherapy services to a public health coaching service) with up to 10 telephone-based health coaching sessions over 6 months
Number of subjects: 374
Study 34243746 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided at discharge from treatment
Number of subjects: 374
Study 36272055 — intervention group
Group type: EXPERIMENTAL
Intervention: Active theta tACS (6 Hz) on the medial prefrontal cortex (mPFC)
Number of subjects: 16
Study 36272055 — intervention group
Group type: COMPARATOR
Intervention: Sham theta tACS
Number of subjects: 16
Study 33249492 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioral therapy for insomnia (dCBT‐I)
Number of subjects: 208
Study 33249492 — intervention group
Group type: COMPARATOR
Intervention: Sleep education
Number of subjects: 208
Study 32382745 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU)
Number of subjects: 222
Study 32382745 — intervention group
Group type: COMPARATOR
Intervention: Topical testosterone (Axiron)
Number of subjects: 222
Study 36389184 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic feedback in VR training module
Number of subjects: 31
Study 36389184 — intervention group
Group type: COMPARATOR
Intervention: Non-haptic group
Number of subjects: 31
Study 33618922 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg
Number of subjects: 24
Study 33618922 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 34537125 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate (MSG)
Number of subjects: 50
Study 34537125 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (RG)
Number of subjects: 50
Study 32202490 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP POCT
Number of subjects: 653
Study 32202490 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 653
Study 32354432 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear aligner therapy (CA)
Number of subjects: 49
Study 32354432 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliance therapy (FA)
Number of subjects: 49
Study 35225119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed physical exercise protocol with dual task (DT) (30 sessions, 2x/week, duration of 60-90 min)
Number of subjects: 26
Study 35225119 — intervention group
Group type: COMPARATOR
Intervention: Standard physical exercise protocol without DT
Number of subjects: 26
Study 35225119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed physical exercise under DT
Number of subjects: 26
Study 36174028 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine management
Number of subjects: 120
Study 36174028 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient clinic appointment
Number of subjects: 120
Study 33594388 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-EBOV vaccine
Number of subjects: 300000
Study 32391919 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (LAmB) 3.0 mg/kg/d
Number of subjects: 102
Study 32391919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole (ivITCZ) induction: 400 mg/d, maintenance: 200 mg/d
Number of subjects: 102
Study 33486058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg administered within 90 minutes of surgery)
Number of subjects: 75
Study 35534456 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 193
Study 35534456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 193
Study 33740360 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids post-surgery
Number of subjects: 200
Study 33740360 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids for non-severe pain
Number of subjects: 200
Study 33740360 — intervention group
Group type: COMPARATOR
Intervention: Black patients
Number of subjects: 200
Study 33740360 — intervention group
Group type: COMPARATOR
Intervention: Intra- and post-operative opioid administration
Number of subjects: 200
Study 32453449 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 214
Study 32453449 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 214
Study 32453449 — intervention group
Group type: COMPARATOR
Intervention: Non-receipt of Care (NC)
Number of subjects: 214
Study 36186981 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraCoronary Artery Retrograde Thrombolysis (ICART)
Number of subjects: 286
Study 36186981 — intervention group
Group type: COMPARATOR
Intervention: Thrombus aspiration or PTCA
Number of subjects: 286
Study 32564482 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling (TC)
Number of subjects: 1446
Study 32564482 — intervention group
Group type: COMPARATOR
Intervention: No telephone counselling (Control)
Number of subjects: 1446
Study 35608484 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal approach to glucose control (intravenous insulin commenced at blood glucose >252 mg/dL, titrated to 180-252 mg/dL)
Number of subjects: 419
Study 35608484 — intervention group
Group type: COMPARATOR
Intervention: Comparator approach to glucose control (insulin commenced at blood glucose >180 mg/dL, titrated to 108-180 mg/dL)
Number of subjects: 419
Study 32917508 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 0
Study 32917508 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32516094 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Load-Velocity Profiling (ILVP)
Number of subjects: 19
Study 32516094 — intervention group
Group type: COMPARATOR
Intervention: Group Load-Velocity Profiling (GLVP)
Number of subjects: 19
Study 35321961 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece SIMOs
Number of subjects: 24
Study 35321961 — intervention group
Group type: COMPARATOR
Intervention: Two-piece SIMOs
Number of subjects: 24
Study 35115706 — intervention group
Group type: EXPERIMENTAL
Intervention: H2HA-Ferritin 20-μg dose (n=5)
Number of subjects: 50
Study 35115706 — intervention group
Group type: EXPERIMENTAL
Intervention: H2HA-Ferritin 60-μg dose in homologous prime-boost regimen (n=25)
Number of subjects: 50
Study 35115706 — intervention group
Group type: EXPERIMENTAL
Intervention: H2HA-Ferritin 60-μg dose in heterologous prime-boost regimen (n=20)
Number of subjects: 50
Study 35115706 — intervention group
Group type: COMPARATOR
Intervention: H2 DNA vaccine (control group, n=5)
Number of subjects: 50
Study 35115706 — intervention group
Group type: EXPERIMENTAL
Intervention: H2HA-Ferritin vaccine
Number of subjects: 50
Study 32060708 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 0
Study 32060708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33596116 — intervention group
Group type: EXPERIMENTAL
Intervention: Taperloc stem
Number of subjects: 38
Study 33596116 — intervention group
Group type: COMPARATOR
Intervention: Mallory-Head stem
Number of subjects: 38
Study 33596116 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stems
Number of subjects: 38
Study 32722793 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U incobotulinumtoxinA
Number of subjects: 38
Study 32722793 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 U incobotulinumtoxinA
Number of subjects: 38
Study 32722793 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U incobotulinumtoxinA
Number of subjects: 38
Study 32146109 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted group (n=291); instructed to refrain from hip flexion >90°, adduction across midline, and internal rotation for 6 weeks.
Number of subjects: 587
Study 32146109 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted group (n=294); no specific restrictions on hip movement.
Number of subjects: 587
Study 32146109 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted group (n=294); no restrictions.
Number of subjects: 587
Study 35666982 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-high patients
Number of subjects: 401
Study 35666982 — intervention group
Group type: COMPARATOR
Intervention: CTC-low patients
Number of subjects: 401
Study 32310156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 25
Study 33279544 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl mesh coverage after thoracoscopic bullectomy
Number of subjects: 204
Study 33279544 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Vicryl mesh)
Number of subjects: 204
Study 32349779 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP/IVE/GDP
Number of subjects: 106
Study 32349779 — intervention group
Group type: COMPARATOR
Intervention: CEOP
Number of subjects: 106
Study 33331126 — intervention group
Group type: EXPERIMENTAL
Intervention: 8888 group (8 hours time-in-bed each night)
Number of subjects: 78
Study 33331126 — intervention group
Group type: EXPERIMENTAL
Intervention: 8888 group
Number of subjects: 78
Study 33331126 — intervention group
Group type: EXPERIMENTAL
Intervention: 8846 group (variable sleep schedule)
Number of subjects: 78
Study 33331126 — intervention group
Group type: EXPERIMENTAL
Intervention: 8486 group (variable sleep schedule)
Number of subjects: 78
Study 33331126 — intervention group
Group type: COMPARATOR
Intervention: 8666 group (stable sleep schedule)
Number of subjects: 78
Study 33331126 — intervention group
Group type: COMPARATOR
Intervention: 8846 group (stable sleep schedule)
Number of subjects: 78
Study 33331126 — intervention group
Group type: EXPERIMENTAL
Intervention: 8486 group
Number of subjects: 78
Study 33331126 — intervention group
Group type: COMPARATOR
Intervention: 8666 group
Number of subjects: 78
Study 33331126 — intervention group
Group type: COMPARATOR
Intervention: 8846 group
Number of subjects: 78
Study 33470281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection alone
Number of subjects: 30
Study 33470281 — intervention group
Group type: EXPERIMENTAL
Intervention: ETDRS panretinal photocoagulation combined with intravitreal ranibizumab
Number of subjects: 30
Study 33470281 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL panretinal photocoagulation combined with intravitreal ranibizumab
Number of subjects: 30
Study 33470281 — intervention group
Group type: COMPARATOR
Intervention: ETDRS group
Number of subjects: 30
Study 33470281 — intervention group
Group type: COMPARATOR
Intervention: PASCAL group
Number of subjects: 30
Study 35100493 — intervention group
Group type: EXPERIMENTAL
Intervention: LC hair essence serum (1 ml diluted with 0.5 ml of 0.9% normal saline, injected once weekly for 8 weeks)
Number of subjects: 62
Study 35100493 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A (50 units injected)
Number of subjects: 62
Study 34880029 — intervention group
Group type: EXPERIMENTAL
Intervention: phacotrabeculectomy
Number of subjects: 124
Study 34880029 — intervention group
Group type: COMPARATOR
Intervention: phacogoniotomy
Number of subjects: 124
Study 36085410 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoRings (ER)
Number of subjects: 556
Study 36085410 — intervention group
Group type: COMPARATOR
Intervention: Standard Colonoscopy (SC)
Number of subjects: 556
Study 32007239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at a rate of 0.4 μg kg‐1 h‐1 for 24 h
Number of subjects: 108
Study 32007239 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 108
Study 32007239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 108
Study 32007239 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 108
Study 35568917 — intervention group
Group type: EXPERIMENTAL
Intervention: True APP therapy
Number of subjects: 206
Study 35568917 — intervention group
Group type: COMPARATOR
Intervention: Sham point stimulation therapy
Number of subjects: 206
Study 33546647 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led exercise and education Positive Living programme (PL programme)
Number of subjects: 49
Study 33546647 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic relationship (TR)
Number of subjects: 49
Study 35872936 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging big data‐assisted arterial chemoembolization combined with 125I seed implantation
Number of subjects: 116
Study 35872936 — intervention group
Group type: COMPARATOR
Intervention: Arterial chemoembolization alone with gemcitabine combined with cisplatin (GP)
Number of subjects: 116
Study 34270979 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention for postpartum contraception
Number of subjects: 234
Study 34270979 — intervention group
Group type: COMPARATOR
Intervention: Control clusters (no home-based intervention)
Number of subjects: 234
Study 34270979 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention
Number of subjects: 234
Study 35726852 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group with beetroot juice supplement (EX&BRJS)
Number of subjects: 40
Study 35726852 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 40
Study 35726852 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EX)
Number of subjects: 40
Study 35726852 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice supplement group (BRJS)
Number of subjects: 40
Study 34476663 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic drugs
Number of subjects: 125
Study 32167605 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day reverse hybrid therapy (dexlansoprazole 60 mg o.d. plus amoxicillin 1 g b.d. for 14 days, and clarithromycin 500 mg plus metronidazole 500 mg b.d. for initial 7 days)
Number of subjects: 248
Study 32167605 — intervention group
Group type: COMPARATOR
Intervention: 14-day concomitant therapy (dexlansoprazole 60 mg o.d. plus amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg b.d. for 14 days)
Number of subjects: 248
Study 32167605 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day reverse hybrid therapy
Number of subjects: 248
Study 32167605 — intervention group
Group type: COMPARATOR
Intervention: 14-day concomitant therapy
Number of subjects: 248
Study 35551624 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning for postural education (4 sessions via web-based Student Education Network, SHAD)
Number of subjects: 408
Study 35551624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 408
Study 35551624 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning for postural education
Number of subjects: 408
Study 34149019 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the Prolapse and Incontinence Knowledge Questionnaire (PIKQ)
Number of subjects: 57
Study 32093647 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy improvement programme (SIP) consisting of 1 day of theory and 4 weeks of practice
Number of subjects: 66
Study 32093647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 66
Study 36450821 — intervention group
Group type: EXPERIMENTAL
Intervention: Vuse Solo Original
Number of subjects: 0
Study 36450821 — intervention group
Group type: COMPARATOR
Intervention: Abstinence
Number of subjects: 0
Study 34612106 — intervention group
Group type: EXPERIMENTAL
Intervention: 2Q‐AF test
Number of subjects: 56
Study 34612106 — intervention group
Group type: EXPERIMENTAL
Intervention: 2Q‐AF score
Number of subjects: 56
Study 34612106 — intervention group
Group type: COMPARATOR
Intervention: �2.00 DS lens flippers
Number of subjects: 56
Study 36328392 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating community protection for friends and family
Number of subjects: 512
Study 36328392 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating community protection for overall society
Number of subjects: 512
Study 36328392 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating community protection for friends and family among white participants
Number of subjects: 512
Study 36328392 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating community protection for overall society among white participants
Number of subjects: 512
Study 36328392 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating community protection for friends and family among ethnically diverse participants
Number of subjects: 512
Study 36328392 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating community protection for overall society among ethnically diverse participants
Number of subjects: 512
Study 33840495 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group (listened to a prerecorded relaxation breathing session before and during the injection)
Number of subjects: 104
Study 33840495 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the injection without a relaxation session)
Number of subjects: 104
Study 33840495 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 104
Study 35872933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined examination (CDUS, MAM, CA153)
Number of subjects: 10821
Study 35872933 — intervention group
Group type: COMPARATOR
Intervention: CDUS
Number of subjects: 10821
Study 35872933 — intervention group
Group type: COMPARATOR
Intervention: MAM
Number of subjects: 10821
Study 35872933 — intervention group
Group type: COMPARATOR
Intervention: CA153
Number of subjects: 10821
Study 32431306 — intervention group
Group type: EXPERIMENTAL
Intervention: Student peer evaluations
Number of subjects: 100
Study 32431306 — intervention group
Group type: EXPERIMENTAL
Intervention: Student self-evaluations
Number of subjects: 100
Study 32431306 — intervention group
Group type: COMPARATOR
Intervention: Faculty evaluations
Number of subjects: 100
Study 33804788 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination status
Number of subjects: 153
Study 33804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and marital status
Number of subjects: 153
Study 33804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider endorsement
Number of subjects: 153
Study 33804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/ethnicity, religion, skills, intention to counsel parents
Number of subjects: 153
Study 33804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentions to counsel parents on HPV vaccination
Number of subjects: 153
Study 33804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to improve vaccination rates
Number of subjects: 153
Study 35486013 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with moxibustion (acu-mox)
Number of subjects: 80
Study 35486013 — intervention group
Group type: COMPARATOR
Intervention: Medication group (ioratadine tablets, 1 tablet daily for 10 days, 3 sessions)
Number of subjects: 80
Study 33243286 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2 mA for 20 min) with working memory training
Number of subjects: 0
Study 33243286 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation with working memory training
Number of subjects: 0
Study 34299780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet with meat product (LCD + MP)
Number of subjects: 36
Study 34299780 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet (LCD)
Number of subjects: 36
Study 32014686 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose systemic interferon-α2b (HDI) following dendritic cell (DC) vaccination
Number of subjects: 0